BACKGROUND AND AIMS: Protease inhibitor (PI)-resistant hepatitis C virus (HCV) variants may be present in substantial numbers in PI-untreated patients according to recent reports. However, influence of these viruses in the clinical course of chronic hepatitis C has not been well characterized. METHODS: The dominant HCV nonstructural 3 (NS3) amino acid sequences were determined in 261 HCV genotype 1b-infected Japanese patients before pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, and investigated the patients' clinical characteristics as well as treatment responses including sustained virological response (SVR) rate. HCV-NS3 sequences were also determined in 39 non-SVR patients after completion of the therapy. RESULTS: Four single mutations (T54S, Q80K, I153V, and D168E) known to confer PI resistance were found in 35 of 261 patients (13.4%), and double mutations (I153V plus T54S/D168E) were found in 6 patients (2.3%). Responses to PEG-IFN/RBV therapy did not differ between patients with and without PI-resistance mutations (mutation group, SVR 48%; wild-type group, SVR 40%; P = 0.38). On the other hand, two mutations appeared in two non-SVR patients after PEG-IFN/RBV therapy (I153V and E168D, 5.1%). CONCLUSIONS: PI-resistance-associated NS3 mutations exist in a substantial proportion of untreated HCV-1b-infected patients. The impact of these mutations in the treatment of PIs is unclear, but clinicians should pay attention to avoid further development of PI resistance.
BACKGROUND AND AIMS: Protease inhibitor (PI)-resistant hepatitis C virus (HCV) variants may be present in substantial numbers in PI-untreated patients according to recent reports. However, influence of these viruses in the clinical course of chronic hepatitis C has not been well characterized. METHODS: The dominant HCV nonstructural 3 (NS3) amino acid sequences were determined in 261 HCV genotype 1b-infected Japanese patients before pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, and investigated the patients' clinical characteristics as well as treatment responses including sustained virological response (SVR) rate. HCV-NS3 sequences were also determined in 39 non-SVR patients after completion of the therapy. RESULTS: Four single mutations (T54S, Q80K, I153V, and D168E) known to confer PI resistance were found in 35 of 261 patients (13.4%), and double mutations (I153V plus T54S/D168E) were found in 6 patients (2.3%). Responses to PEG-IFN/RBV therapy did not differ between patients with and without PI-resistance mutations (mutation group, SVR 48%; wild-type group, SVR 40%; P = 0.38). On the other hand, two mutations appeared in two non-SVR patients after PEG-IFN/RBV therapy (I153V and E168D, 5.1%). CONCLUSIONS: PI-resistance-associated NS3 mutations exist in a substantial proportion of untreated HCV-1b-infectedpatients. The impact of these mutations in the treatment of PIs is unclear, but clinicians should pay attention to avoid further development of PI resistance.
Authors: X Tong; A Arasappan; F Bennett; R Chase; B Feld; Z Guo; A Hart; V Madison; B Malcolm; J Pichardo; A Prongay; R Ralston; A Skelton; E Xia; R Zhang; F G Njoroge Journal: Antimicrob Agents Chemother Date: 2010-03-22 Impact factor: 5.191
Authors: Xiao Tong; Stephane Bogen; Robert Chase; V Girijavallabhan; Zhuyan Guo; F George Njoroge; Andrew Prongay; Anil Saksena; Angela Skelton; Ellen Xia; Robert Ralston Journal: Antiviral Res Date: 2007-12-28 Impact factor: 5.970
Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato Journal: N Engl J Med Date: 1996-01-11 Impact factor: 91.245
Authors: Yi Zhou; Doug J Bartels; Brian L Hanzelka; Ute Müh; Yunyi Wei; Hui-May Chu; Ann M Tigges; Debra L Brennan; B Govinda Rao; Lora Swenson; Ann D Kwong; Chao Lin Journal: Antimicrob Agents Chemother Date: 2007-10-15 Impact factor: 5.191
Authors: Christoph Welsch; Francisco S Domingues; Simone Susser; Iris Antes; Christoph Hartmann; Gabriele Mayr; Andreas Schlicker; Christoph Sarrazin; Mario Albrecht; Stefan Zeuzem; Thomas Lengauer Journal: Genome Biol Date: 2008-01-23 Impact factor: 13.583
Authors: Anna S Nishiya; Cesar de Almeida-Neto; Suzete C Ferreira; Cecília S Alencar; Claudia Di-Lorenzo-Oliveira; José E Levi; Nanci A Salles; Alfredo Mendrone; Ester C Sabino Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240